Cue Biopharma Stock Forecast - Simple Regression
| CUE Stock | USD 0.38 0.02 5.56% |
Cue Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Cue Biopharma stock prices and determine the direction of Cue Biopharma's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Cue Biopharma's historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time, the RSI of Cue Biopharma's share price is approaching 44 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Cue Biopharma, making its price go up or down. Momentum 44
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.1) | EPS Estimate Current Year (0.41) | EPS Estimate Next Year (0.48) | Wall Street Target Price 5 | EPS Estimate Current Quarter (0.09) |
Using Cue Biopharma hype-based prediction, you can estimate the value of Cue Biopharma from the perspective of Cue Biopharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Cue Biopharma using Cue Biopharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Cue using crowd psychology based on the activity and movement of Cue Biopharma's stock price.
Cue Biopharma Short Interest
A significant increase or decrease in Cue Biopharma's short interest from the previous month could be a good indicator of investor sentiment towards Cue. Short interest can provide insight into the potential direction of Cue Biopharma stock and how bullish or bearish investors feel about the market overall.
200 Day MA 0.6751 | Short Percent 0.0158 | Short Ratio 1.16 | Shares Short Prior Month 368.8 K | 50 Day MA 0.4466 |
Cue Relative Strength Index
The Simple Regression forecasted value of Cue Biopharma on the next trading day is expected to be 0.24 with a mean absolute deviation of 0.05 and the sum of the absolute errors of 3.04.Cue Biopharma Hype to Price Pattern
Investor biases related to Cue Biopharma's public news can be used to forecast risks associated with an investment in Cue. The trend in average sentiment can be used to explain how an investor holding Cue can time the market purely based on public headlines and social activities around Cue Biopharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Cue Biopharma's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Cue Biopharma.
Cue Biopharma Implied Volatility | 1.19 |
Cue Biopharma's implied volatility exposes the market's sentiment of Cue Biopharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cue Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cue Biopharma stock will not fluctuate a lot when Cue Biopharma's options are near their expiration.
The Simple Regression forecasted value of Cue Biopharma on the next trading day is expected to be 0.24 with a mean absolute deviation of 0.05 and the sum of the absolute errors of 3.04. Cue Biopharma after-hype prediction price | USD 0.37 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Cue Biopharma to cross-verify your projections. Open Interest Against 2026-04-17 Cue Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Cue Biopharma's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Cue Biopharma's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Cue Biopharma stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Cue Biopharma's open interest, investors have to compare it to Cue Biopharma's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Cue Biopharma is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Cue. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Cue Biopharma Additional Predictive Modules
Most predictive techniques to examine Cue price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cue using various technical indicators. When you analyze Cue charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Cue Biopharma Simple Regression Price Forecast For the 27th of January
Given 90 days horizon, the Simple Regression forecasted value of Cue Biopharma on the next trading day is expected to be 0.24 with a mean absolute deviation of 0.05, mean absolute percentage error of 0, and the sum of the absolute errors of 3.04.Please note that although there have been many attempts to predict Cue Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cue Biopharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Cue Biopharma Stock Forecast Pattern
| Backtest Cue Biopharma | Cue Biopharma Price Prediction | Buy or Sell Advice |
Cue Biopharma Forecasted Value
In the context of forecasting Cue Biopharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Cue Biopharma's downside and upside margins for the forecasting period are 0 and 8.75, respectively. We have considered Cue Biopharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Cue Biopharma stock data series using in forecasting. Note that when a statistical model is used to represent Cue Biopharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.6902 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0498 |
| MAPE | Mean absolute percentage error | 0.1355 |
| SAE | Sum of the absolute errors | 3.0401 |
Predictive Modules for Cue Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cue Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cue Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cue Biopharma After-Hype Price Density Analysis
As far as predicting the price of Cue Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cue Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cue Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cue Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Cue Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cue Biopharma's historical news coverage. Cue Biopharma's after-hype downside and upside margins for the prediction period are 0.02 and 8.82, respectively. We have considered Cue Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cue Biopharma is extremely dangerous at this time. Analysis and calculation of next after-hype price of Cue Biopharma is based on 3 months time horizon.
Cue Biopharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Cue Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cue Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cue Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.75 | 8.51 | 0.01 | 0.36 | 8 Events / Month | 5 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.38 | 0.37 | 2.63 |
|
Cue Biopharma Hype Timeline
On the 26th of January Cue Biopharma is traded for 0.38. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of 0.36. Cue is anticipated to decline in value after the next headline, with the price expected to drop to 0.37. The average volatility of media hype impact on the company price is over 100%. The price depreciation on the next news is expected to be -2.63%, whereas the daily expected return is currently at -0.75%. The volatility of related hype on Cue Biopharma is about 1751.03%, with the expected price after the next announcement by competition of 0.74. About 23.0% of the company shares are held by institutions such as insurance companies. The book value of Cue Biopharma was currently reported as 0.17. The company recorded a loss per share of 0.41. Cue Biopharma had not issued any dividends in recent years. Considering the 90-day investment horizon the next anticipated press release will be in about 8 days. Check out Historical Fundamental Analysis of Cue Biopharma to cross-verify your projections.Cue Biopharma Related Hype Analysis
Having access to credible news sources related to Cue Biopharma's direct competition is more important than ever and may enhance your ability to predict Cue Biopharma's future price movements. Getting to know how Cue Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cue Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PFE | Pfizer Inc | 0.09 | 6 per month | 1.09 | 0.03 | 2.02 | (1.92) | 7.97 | |
| VCV | Invesco California Value | 0.16 | 8 per month | 0.78 | (0.01) | 1.53 | (1.55) | 3.42 | |
| MRK | Merck Company | 1.34 | 7 per month | 1.09 | 0.17 | 3.59 | (1.98) | 8.09 | |
| NMFC | New Mountain Finance | 0.13 | 5 per month | 1.01 | (0.05) | 1.66 | (1.69) | 5.28 | |
| AA | Alcoa Corp | 2.39 | 7 per month | 2.42 | 0.19 | 6.55 | (4.82) | 18.46 | |
| KOS | Kosmos Energy | (0.01) | 11 per month | 0.00 | (0.03) | 10.27 | (5.99) | 25.11 | |
| GGG | Graco Inc | 1.63 | 6 per month | 1.19 | 0.01 | 2.46 | (1.90) | 6.74 | |
| NSSC | NAPCO Security Technologies | (0.61) | 9 per month | 0.00 | (0.09) | 3.98 | (4.00) | 14.26 | |
| SRTOY | Sartorius Stedim Biotech | 0.00 | 0 per month | 1.97 | (0.01) | 2.92 | (3.28) | 14.94 | |
| KNX | Knight Transportation | (0.26) | 9 per month | 1.86 | 0.1 | 3.84 | (2.96) | 8.76 |
Other Forecasting Options for Cue Biopharma
For every potential investor in Cue, whether a beginner or expert, Cue Biopharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Cue Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Cue. Basic forecasting techniques help filter out the noise by identifying Cue Biopharma's price trends.Cue Biopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cue Biopharma stock to make a market-neutral strategy. Peer analysis of Cue Biopharma could also be used in its relative valuation, which is a method of valuing Cue Biopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Cue Biopharma Market Strength Events
Market strength indicators help investors to evaluate how Cue Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cue Biopharma shares will generate the highest return on investment. By undertsting and applying Cue Biopharma stock market strength indicators, traders can identify Cue Biopharma entry and exit signals to maximize returns.
Cue Biopharma Risk Indicators
The analysis of Cue Biopharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Cue Biopharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting cue stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.36 | |||
| Standard Deviation | 8.24 | |||
| Variance | 67.86 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Cue Biopharma
The number of cover stories for Cue Biopharma depends on current market conditions and Cue Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Cue Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Cue Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Cue Biopharma Short Properties
Cue Biopharma's future price predictability will typically decrease when Cue Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Cue Biopharma often depends not only on the future outlook of the potential Cue Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cue Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 56.3 M | |
| Cash And Short Term Investments | 23.4 M |
Check out Historical Fundamental Analysis of Cue Biopharma to cross-verify your projections. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.41) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.